Needham analyst Ami Fadia initiated coverage of Revolution Medicines with a Buy rating and $31 price target. Revolution Medicines tri-complex platform is in the lead in efforts to target mutations in GTP- bound RAS(ON) proteins and has demonstrated promising pre-clinical data, Fadia tells investors in a research note. Clinical data from RMC-6291 in 2023 could meaningfully de-risk the RAS(ON) platform, the analyst contends.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RVMD:
- Revolution Medicines initiated with a Buy at Needham
- Revolution Medicines price target raised to $32 from $30 at H.C. Wainwright
- Revolution to regain rights to RMC-4630 following Sanofi deal termination
- Sanofi terminates SHP2 Inhibitor development pact with Revolution Medicines
- Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration
